Vivani Medical, Inc. (Nasdaq: VANI), a pioneer in biopharmaceutical innovations, has reached a pivotal milestone as the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for NPM-119, marking a significant advancement in the treatment of type 2 diabetes. This approval also lifts a previous clinical hold, allowing the initiation […]
Novo Nordisk, a leading Danish pharmaceutical company, has completed a significant acquisition of Ziylo, a biotechnology spin-out from the University of Bristol, for a deal potentially worth over $800 million. This acquisition grants Novo Nordisk full rights to Ziylo’s innovative glucose binding molecules, crucial for the development of glucose responsive insulins. Strategic Importance of the […]
